Clinical Trial

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-07
notable Primary completion pushed: 2026-04-30 -> 2026-06-05 2026-08-07
minor Completion pushed: 2026-06-30 -> 2027-01-30 2026-08-07
Trial Details
NCT Number NCT06640257
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Psoriatic Arthritis
Enrollment 208 participants
Start Date 2024-11-04
Primary Completion 2026-06-05 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06